NDAINHALATIONPOWDER
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
ARMONAIR RESPICLICK (fluticasone propionate) by Teva is signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action of fluticasone propionate ointment, 0. Approved for asthma, chronic obstructive pulmonary disease. First approved in 2017.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARMONAIR RESPICLICK is a fluticasone propionate inhalation powder approved in 2017 for asthma and COPD. It is a corticosteroid that reduces inflammation and modulates immune function in the airways through signaling and protein regulation mechanisms. The RespiClick device delivers the powder formulation via inhalation for direct lung targeting.
Peak14.7 years to LOE
ARMONAIR is at peak maturity with Teva managing a stable, established franchise in a highly competitive respiratory market; brand teams are focused on maintaining market position rather than growth expansion.
Mechanism of Action
signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action of fluticasone propionate ointment, 0.005% in corticosteroid-responsive dermatoses is unknown.
Indications (2)
Clinical Trials (20)
A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
Started May 2026
304 enrolled
Asthma
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Started Dec 2024
724 enrolled
Asthma
Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old
Started May 2024
30 enrolled
Asthma
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Started Aug 2023
2,700 enrolled
Asthma
Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers
Started Aug 2023
34 enrolled
Bioequivalence
Worked on ARMONAIR RESPICLICK at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.